Skip to content

Monthly archives: July, 2017

PD-1 inhibitor associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation

Congratualations to Dr Shaun Chou, with the paper “PD-1 inhibitor associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation – report of four cases” accepted in Journal of Cutaneous Pathology last week. This is a paper about four rare cases of atypical lichenoid reactions with histological blistering, that histologically mimicked paraneoplastic pemphigus. All of the …

Anti-melanoma therapies and colour changes in moles

Various cutaneous side-effects have been reported with anti-melanoma systemic therapies. BRAF inhibitors, MEK inhibitors, anti-PD1 and anti-CTLA4 molecules have changed the prognosis of patients with metastatic melanoma, improving their chances of survival. Some side effects appear in these patients, including changes in nevi (moles). We have reviewed the changes in our patients on dabrafenib, vermurafenib …